FDA 483 - Far East Summit LLC - April 18, 2025

Far East Summit LLC received a Form 483 with 22 observations detailing significant deficiencies in its dietary supplement manufacturing operations. The firm failed to establish adequate product and component specifications, conduct proper identity testing, and qualify suppliers, with several issues being repeat observations. Key concerns include unqualified quality control personnel, inadequate master and batch manufacturing records, poor hygienic practices, and a lack of effective controls against foreign material contamination.